Celldex Therapeutics, Inc. (NASDAQ:CLDX) has earned an average rating of “Hold” from the nine ratings firms that are currently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $8.13.

CLDX has been the subject of several recent research reports. WBB Securities reiterated a “buy” rating and issued a $10.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, December 6th. HC Wainwright reiterated a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, November 7th. Finally, BidaskClub downgraded Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 11th.

Shares of Celldex Therapeutics (NASDAQ CLDX) traded down $0.03 during mid-day trading on Friday, reaching $2.35. The company’s stock had a trading volume of 1,095,100 shares, compared to its average volume of 1,178,944. Celldex Therapeutics has a 12-month low of $2.20 and a 12-month high of $3.94. The company has a market capitalization of $323.64, a P/E ratio of -2.33 and a beta of 2.57.

Institutional investors have recently made changes to their positions in the stock. Northern Trust Corp raised its holdings in shares of Celldex Therapeutics by 12.2% during the second quarter. Northern Trust Corp now owns 2,020,797 shares of the biopharmaceutical company’s stock valued at $4,992,000 after acquiring an additional 219,661 shares in the last quarter. Virtu KCG Holdings LLC raised its holdings in shares of Celldex Therapeutics by 458.6% during the second quarter. Virtu KCG Holdings LLC now owns 117,770 shares of the biopharmaceutical company’s stock valued at $291,000 after acquiring an additional 96,687 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Celldex Therapeutics by 7.8% during the second quarter. Vanguard Group Inc. now owns 9,774,858 shares of the biopharmaceutical company’s stock valued at $24,143,000 after acquiring an additional 708,095 shares in the last quarter. Meditor Group Ltd raised its holdings in shares of Celldex Therapeutics by 8.8% during the third quarter. Meditor Group Ltd now owns 6,312,700 shares of the biopharmaceutical company’s stock valued at $18,054,000 after acquiring an additional 512,700 shares in the last quarter. Finally, Swiss National Bank raised its holdings in shares of Celldex Therapeutics by 27.4% during the second quarter. Swiss National Bank now owns 203,700 shares of the biopharmaceutical company’s stock valued at $503,000 after acquiring an additional 43,800 shares in the last quarter. Institutional investors own 52.14% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://theolympiareport.com/2018/02/13/analysts-set-celldex-therapeutics-inc-cldx-pt-at-8-13.html.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.